Evidence map›Paper›PMID 41896701›Full record

Trial reportBJU international2026

Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial.

Nikita Sushentsev, Anne Y Warren, Richard Colling, Clare Verrill, Ekaterina Pazukhina, Oleg Blyuss, Alexey Zaikin, Tyler M Seibert, Tristan Barrett, Jon Oxley and 6 more

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02044172 (The ProtecT Trial - Evaluating the Effectiveness of Treatments for Clinically Localised Prostate Cancer), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02044172 naactive not recruitingnot on this map

The ProtecT Trial - Evaluating the Effectiveness of Treatments for Clinically Localised Prostate Cancer

TypeinterventionalSponsorUniversity of OxfordRan2001 to 2027Enrolled82,849ConditionsProstate CancerArmsRadical prostatectomy, Conformal radiation therapy, Active monitoring
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Germline polygenic score for prostate cancer aggressiveness.medRxiv : the preprint server for health sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nikita SushentsevDepartment of Radiology, University of Cambridge, Cambridge, UK.ORCID 0000-0003-4500-9714
Anne Y WarrenDepartment of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Richard CollingNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Clare VerrillNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Ekaterina PazukhinaWolfson Institute of Population Health, Queen Mary University of London, London, UK.
Oleg BlyussWolfson Institute of Population Health, Queen Mary University of London, London, UK.
Alexey ZaikinDepartment of Women's Cancer, Institute for Women's Health, University College London, London, UK.
Tyler M SeibertDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, San Diego, CA, USA.
Tristan BarrettDepartment of Radiology, University of Cambridge, Cambridge, UK.
Jon OxleyDepartment of Histopathology, North Bristol Hospitals Trust, Bristol, UK.ORCID 0000-0002-4348-0273
Ian G MillsNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Richard J BryantNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.ORCID 0000-0002-8330-9251
J Athene LanePopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0002-7578-4925
Jenny L DonovanPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
David E NealNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Freddie C HamdyNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

Funding

Cancer Research UK Cambridge Centre C9685/A25177Cancer Research UK Cambridge Centre, and NIHR NIHR203312National Institute for Health and Care Research
6 · The paper itself

Abstract

objectivesTo retrospectively analyse the results of the Prostate Testing for Cancer and Treatment (ProtecT; ClinicalTrials.gov identifier: NCT02044172) trial to establish the association between cribriform-positive and -negative prostate cancer (PCa) and the 15-year risk of metastasis or death from PCa in patients who underwent radical prostatectomy (RP). PATIENTS AND

methodsBetween 1999 and 2009, the ProtecT phase 3 clinical trial enrolled 1643 men with clinically localised PCa who were randomised to receive active monitoring, RP, or radiotherapy. In this secondary analysis of the trial, a centralised histopathological review was conducted on available RP pathology slides to classify patients as cribriform-positive if they had invasive cribriform carcinoma and/or intraductal carcinoma. The primary outcome was a composite of progression to metastatic disease or death from PCa. Exposures included age, prostate-specific antigen density, RP Grade Group (GG), pathological T stage (pT), and cribriform status. Multivariable Cox proportional hazards regression models assessed 15-year risk. Cumulative incidence curves were compared using the Gray test.

resultsOf 480 men with RP specimens reviewed, 143 (30%) had cribriform-positive disease and 337 (70%) had cribriform-negative disease. All 21 metastatic or lethal events occurred exclusively in the cribriform-positive group (15-year cumulative incidence 14%). Within the cribriform-positive cohort, risk was concentrated in patients with pT3b stage and/or GG ≥3 (15-year cumulative incidence 27%). In multivariable analysis of cribriform-positive patients, pT3b stage (hazard ratio [HR] 8.19, 95% confidence interval [CI] 2.39-28.10; P < 0.001) and GG 3 disease (HR 5.12, 95% CI 1.59-16.40; P = 0.006) were independent predictors of adverse outcomes. Conversely, cribriform-positive patients with GG 2 and ≤pT3a had a 15-year event rate of only 3%.

conclusionIn the ProtecT trial, the 15-year risk of metastasis or death after RP was a binary outcome defined by cribriform status. The concentration of risk in men with cribriform-positive, high-grade and/or pT3b tumours identifies a target population for adjuvant therapy trials, while supporting management de-escalation for most RP patients.

Indexed as

AdenocarcinomaProstatectomyProstatic NeoplasmsAgedDisease ProgressionHumansMaleMiddle AgedNeoplasm StagingRetrospective StudiesTreatment Outcomecribriform adenocarcinomaintraductal carcinomametastasisprostate cancerradical prostatectomy

Identifiers

PMID41896701
PMCPMC13168917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.